A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Key facts
- Who runs it
- David Bushnell
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 30 Sept 2022
- Ended
- 23 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lutathera
- Azedra
- Record updated
- 29 April 2024
- Why it stopped
- Azedra withdrawn from US market
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Ability to understand and willingness to provide informed consent; legally authorized representative will not be utilized compliant with the principles of good clinical practice (i.e., ICH E6(R2))
- Stated willingness to comply with all study procedures and availability for duration of study
- Aged ≥ 18 years to 80 years at the time of study drug administration
- Pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be:; a well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2) with a primary tumor location believed to be midgut, or,; pheochromocytoma, or,; paraganglioma
- Recommended to receive LUTATHERA® or AZEDRA® therapy
- Disease measuring ≥ 1.5 cm in diameter on CT or MRI as measured per RECIST
- Adequate performance status (ECOG of 0 or 1; or KPS of >70)
- Agrees to contraception during therapy
- Agreement to adhere to Lifestyle Considerations throughout study duration
Who cannot take part
- Surgery, radiation therapy, or chemotherapy ≤ 4 weeks of C1D1. (Toxicities from prior therapies should have resolved to ≤ CTCAE grade 1 or a new baseline established)
- Prior peptide-receptor radiotherapy (PRRT)
- Therapeutic investigational drug within 4 weeks of C1D1 (imaging agents are acceptable)
- A concurrent malignancy that, in the opinion of the investigator, would cause a safety risk by delaying therapy or confound/negatively impact study objectives (documentation of the rationale must be provided)
- Patients unable to discontinue medications known to affect MIBG uptake (unless approved by the PI or designee)
- Prior external beam radiation dose of >16 Gy to the kidneys
- Prior external beam radiation (including brachytherapy) involving 25% of the bone marrow (excluding scatter doses of 5 Gy) as estimated by a radiation oncologist
- At least one tumor site where the calculated safe radiation dose to that tumor site is 25% higher using the combined therapy compared to Lutathera alone; Participants who do not meet this criteria are invited to participate in the comparator arm to receive standard Lutathera treatment as indicated by their physicians
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Octreoscan® or Netspot™; Participants meeting the above criteria will receive one cycle of standard Lutathera treatment (200 millicuries) as well as a tracer dose of Azedra for imaging. Participants will then undergo protocol specific imaging to calculate the radiation dose to the kidneys, the bone marrow, and to the tumor lesions; To continue on study and receive the combined therapy, a participant's imaging must demonstrate one of the following:
- History of congestive heart failure with a history of cardiac ejection fraction ≤ 35%
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Patient with increased fall risk in the opinion of healthcare professionals
- Women who are pregnant
- Women who are breast feeding
- Proteinuria grade 2 (i.e., 2+ proteinuria)
- At least one tumor that is positive for Azedra but negative for Lutathera in addition to Lutathera positive tumors, or,
Where in United States
- Holden Comprehensive Cancer CenterIowa City, United States
About the trial
What the trial wants to find out
This study is designed to identify the best tolerated doses of Lutathera® and Azedra® when co-administered to treat midgut neuroendocrine tumors. These drugs are radioactive drugs, known as radionuclide therapy, and are both approved in the treatment of midgut neuroendocrine tumor as single agents (not together). Currently, the safest and best tolerated doses of these drugs (when combined) is unknown. That is the purpose of this clinical trial.
The 2 groups in the trial
- Combination TherapyTreatment being tested
Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
Treatment: Lutathera and Azedra
- Lutathera® onlyExisting treatment, for comparison
Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
Treatment: Lutathera
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors
- Record updated
- 29 April 2024